Case Report *Open Access*

Journal of Clinical Oncology & Advanced Therapy

DOI: doi.org/10.63721/25JCOAT0109

Dermatological Toxicity of Bleomycin

Melisa Hunis[1] and Adrián Hunis[*2]

[1]*School of Medicine, Maimonides University, Argentina*
[2]*School of Medicine, University of Buenos Aires, Argentina*

Citation: Melisa Hunis MD, Adrián Hunis MD (2025) Dermatological Toxicity of Bleomycin. J.of Clin Onco & Adv Thpy 1(3),01-06. WMJ/ JCOAT-109

Abstract

Background: *Bleomycin is a glycopeptide antibiotic that has played a pivotal role in oncology for over five decades. While pulmonary toxicity has historically attracted the greatest clinical attention, dermatological adverse effects are equally distinctive, pathognomonic, and often underestimated. These cutaneous events, particularly the striking flagellate erythema, not only impact patients' quality of life but also serve as a window into the drug's unique pharmacology and tissue-specific toxicity. Methods: We performed a comprehensive review of the literature, integrating historical context, mechanistic insights, clinical case descriptions, and therapeutic considerations. Results: Dermatological toxicity was found to occur in 8–20% of treated patients, manifesting primarily as linear erythematous streaks that progress to hyperpigmentation. Histopathology reveals dermal inflammation, melanophages, and vacuolar degeneration, reflecting drug accumulation in skin devoid of bleomycin hydrolase. Conclusion: Recognition of these cutaneous toxicities is essential for the practicing oncologist. Their presence is seldom life-threatening, but they inform patient management, highlight the delicate balance between efficacy and toxicity, and remind us of the clinical vigilance required in modern oncologic practice.*

***Corresponding author:** Adrian Hunis, Mailing, School of Medicine, University of Buenos Aires, Argentina.

Submitted: 21.08.2025 **Accepted:** 25.08.2025 **Published:** 04.09.2025

History and Pharmacology of Bleomycin

Bleomycin was first isolated in 1966 by Umezawa from cultures of Streptomyces verticillus, inaugurating a new era in antibiotic-based antineoplastic therapy. Unlike conventional cytotoxic agents, bleomycin belongs to the class of glycopeptide antibiotics, whose molecular architecture allows selective DNA binding. The drug intercalates into double-stranded DNA and, in the presence of oxygen and a metal ion cofactor (commonly iron), generates free radicals capable of inducing both single- and double-strand breaks. This mechanism is particularly active during the G2 phase of the cell cycle, explaining the drug's phase-specific cytotoxicity. Pharmacokinetically, bleomycin is hydrophilic, with limited central nervous system penetration. It is distributed in highly

vascularized tissues but accumulates in the skin and lungs, where bleomycin hydrolase is absent or scarce. This deficiency is the biochemical cornerstone of both its dermatological and pulmonary toxicity. Elimination is primarily renal, and impaired kidney function significantly increases the risk of adverse events.

Current Role in Antitumor Pharmacopoeia

Bleomycin, despite being a drug from the 20th century, continues to occupy a singular niche in modern oncology. Its most enduring contribution has been within the BEP regimen—bleomycin, etoposide, and cisplatin—for germ cell tumors. This combination transformed testicular cancer, once uniformly fatal in advanced stages, into a paradigm of curable solid malignancy with survival rates exceeding 80%. In Hodgkin lymphoma, bleomycin was an integral component of the ABVD regimen, long considered the gold standard worldwide. Yet, contemporary studies, such as the RATHL trial, have demonstrated that bleomycin can often be omitted after a favorable interim PET scan without compromising disease control. Thus, while newer targeted therapies and immunotherapies dominate today's discourse, bleomycin persists in highly curative regimens where its contribution remains irreplaceable.

Current Clinical Indications

In clinical practice, bleomycin is indicated across both genders for specific neoplastic contexts. Its primary indication remains germ cell tumors—both testicular and, less commonly, ovarian. In Hodgkin lymphoma, its use has diminished in intensity-modulated regimens but it continues to appear, particularly in low-resource settings where PET-adapted strategies are not universal. Other contexts include squamous cell carcinomas of the head and neck, cervix, and skin, though such applications have become rare in the era of immunotherapy and targeted approaches. Importantly, susceptibility to toxicity is not markedly sex-dependent, but age, cumulative dose, and renal function critically shape the individual's risk profile.

Pathophysiology of Dermatological Toxicity

The cutaneous toxicity of bleomycin is rooted in a fundamental enzymatic absence: the skin expresses negligible levels of bleomycin hydrolase, the enzyme responsible for drug inactivation. This biological vulnerability renders the skin a privileged site of drug accumulation. Once sequestered in dermal tissues, bleomycin catalyzes oxidative reactions that damage keratinocytes, endothelial cells, and extracellular matrix. The result is a spectrum of pathology ranging from erythematous inflammation to fibrotic sclerosis. Flagellate erythema, the most emblematic lesion, has an additional mechanistic dimension: linear streaks are thought to emerge from microtrauma or scratching, which promotes local drug release and heightened inflammatory response. Histological studies consistently reveal dermal edema, perivascular lymphocytic infiltrates, melanophages, and vacuolar degeneration at the dermoepidermal junction—hallmarks that underscore the unique interplay between pharmacology and cutaneous physiology.

Clinical Aspects and Illustrative Case

We report the case of a 35-year-old woman with an ovarian germ cell tumor treated with a platinum-based regimen including bleomycin. After her third cycle, she developed multiple pruritic, erythematous, whip-like streaks across her trunk and back. Over subsequent weeks, these lesions evolved into persistent hyperpigmented lines, emblematic of bleomycin-induced flagellate erythema. The case exemplifies not only the pathognomonic morphology but also the psychosocial burden, as patients often describe profound distress due to the striking appearance of these lesions. Such visible cutaneous reactions, while benign in prognosis, often carry significant symbolic weight, reminding both patient and clinician of the drug's double-edged therapeutic profile.

Figure 1: Flagellate erythema due to bleomycin (Courtesy of Dr. Adrián Hunis).

Figure 1: Flagellate erythema due to bleomycin (Courtesy of Dr. Adrián Hunis).

Figure 2: Flagellate erythema due to bleomycin (Courtesy of Dr. Adrián Hunis).



Figure 3: Flagellate erythema due to bleomycin (Courtesy of Dr. Adrián Hunis).

Figure 4: Flagellate erythema due to bleomycin (Courtesy of Dr. Adrián Hunis).

Figure 5: Flagellate erythema due to bleomycin (Courtesy of Dr. Adrián Hunis).

Systemic Implications

Unlike bleomycin's pulmonary toxicity, which can be dose-limiting and potentially fatal, cutaneous manifestations rarely threaten life. Nonetheless, they are not devoid of systemic significance. The occurrence of dermatological toxicity often reflects cumulative drug exposure and may serve as a clinical harbinger of intolerance to further cycles. In this sense, cutaneous events, though benign in isolation, may inform therapeutic decision-making, prompting dose reduction or discontinuation. Their systemic impact is therefore indirect, influencing oncologic strategy through the prism of patient tolerability.

Management

Management of bleomycin-induced cutaneous toxicity is predominantly supportive. Topical corticosteroids and emollients ameliorate inflammation and restore skin barrier integrity. Oral antihistamines alleviate pruritus, often the most distressing symptom. Photoprotection is essential, as ultraviolet exposure may exacerbate pigmentary changes. Severe or intolerable cases may necessitate dose reduction or cessation, though such measures must be balanced against the drug's indispensable oncologic efficacy. Importantly, dermatologic toxicity usually resolves gradually after bleomycin discontinuation, but residual hyperpigmentation can persist for months or years, representing a permanent marker of therapy. Patient counseling, therefore, is a key therapeutic component, aligning expectations and fostering resilience in the face of visible, albeit harmless, sequelae.

Table 1: Clinical Manifestations of Bleomycin-Induced Cutaneous Toxicity

Manifestation	Frequency	Description
Flagellate erythema	8–20%	Linear whip-like streaks; pathognomonic
Hyperpigmentation	Common	Post-inflammatory, may persist long-term
Scleroderma-like changes	Rare	Induration and dermal fibrosis
Acral erythema	Occasional	Palmar/plantar erythema and discomfort

Table 2: Cutaneous vs Pulmonary Toxicity of Bleomycin

Toxicity	Pathophysiology	Clinical Impact
Cutaneous	Drug accumulation due to absent hydrolase	Erythema, pigmentation, QoL impairment
Pulmonary	ROS-mediated endothelial damage and fibrosis	Life-threatening; limits cumulative dose

Conclusions

Bleomycin's dermatological toxicity, particularly flagellate erythema, represents one of the most visually striking drug reactions in oncology. While it does not compromise survival, its semiological distinctiveness and psychosocial impact render it clinically significant. In a broader sense, these cutaneous reactions symbolize the intersection of pharmacology and human physiology—where therapeutic triumph is tempered by biological vulnerability. For the oncologist, recognition of these toxicities ensures judicious clinical decision-making, balancing curative intent with quality of life. In the patient's narrative, they are an indelible reminder of both the ordeal of cancer treatment and the resilience borne in its course.

References

1. H Umezawa, M Ishizuka, K Maeda, T Takeuchi (1967) Studies on bleomycin. Cancer 20: 891-895.
2. Oken MM (1976) Bleomycin-induced flagellate erythema. Cancer 37: 201-205.
3. Yamamoto T (1995) Bleomycin-induced scleroderma. Dermatology 190: 231-235.
4. Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest. 120: 617-624.
5. Engert A (2016) RATHL trial. N Engl J Med. 374: 2419-2430.
6. Navarro-Triviño FJ (2020) Flagellate erythema: a review. J Eur Acad Dermatol Venereol. 34: 238-246.
7. López V (2011) Cutaneous toxicity of bleomycin. Clin Transl Oncol. 13: 148-150.
8. Gupta R (2004) Flagellate erythema due to bleomycin. Indian J Dermatol Venereol Leprol. 70: 376-377.
9. Horie C (2014) Mechanisms of bleomycin toxicity. Lab Invest. 94: 236-247.
10. Loo WJ (2013) Flagellate erythema: pathophysiology and management. Clin Exp Dermatol. 38: 225-229.
11. Rajesh A (2012) Cutaneous bleomycin reactions. Australas J Dermatol. 53: 219-223.
12. Dasanu CA (2010) Bleomycin-induced flagellate dermatitis. Conn Med. 74: 403-405.
13. De Wit R (2001) BEP regimen in testicular cancer. J Clin Oncol. 19: 2128-2138.
14. Canellos GP (1975) ABVD in Hodgkin's lymphoma. Cancer. 36: 252-259.
15. Yamamoto T (2006) Pigmentation changes with bleomycin. J Dermatol. 33: 97-101.
16. Visscher MO (2015) Dermatologic effects of chemotherapy. Pediatr Blood Cancer 62: 1601-1608.

17. Grunewald J (2002) Bleomycin and fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 19: 223-230.

18. Puri N (2013) Drug-induced hyperpigmentation. Indian J Dermatol 58:409.